Combination therapy with lenvatinib and anti-PD-1 antibodies for unresectable or advanced hepatocellular carcinoma: A real-world study.

Hui-Chuan Sun,Xiao-Dong Zhu,Cheng Huang,Ying-Hao Shen,Ning-Ling Ge,Yi Chen,Chang-Jun Tan,Jian Zhou,Jia Fan

Combination therapy with lenvatinib and anti-PD-1 antibodies for unresectable or advanced hepatocellular carcinoma: A real-world study.

2020

Hui-Chuan Sun
Xiao-Dong Zhu
Cheng Huang
Ying-Hao Shen
Ning-Ling Ge
Yi Chen
Chang-Jun Tan
Jian Zhou
Jia Fan

e16610Background: Combination therapy of anti-angiogenic therapy and anti-PD-1 antibody had shown promising anti-tumor effects for advanced hepatocellular carcinoma (HCC) in clinical trials. Here w...

Keywords:

Oncology
Internal medicine
Lenvatinib
anti pd 1
Pathology
Hepatocellular carcinoma
Combination therapy
Medicine
Antibody

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations